Researchers tested a new class of imidazolium-based ionic liquids proposed as energy-efficient CO2 capture solvents. One compound with a twelve-carbon chain, IL-9, strongly inhibited human acetylcholinesterase and butyrylcholinesterase in blood samples, with IC50 values of 3.64 and 0.87 micromolar respectively. Shorter-chain analogs showed minimal effects, and the long-chain compound also caused measurable red blood cell lysis. The study, published in Ionics, used docking simulations and hemolysis assays to assess risks. While these ionic liquids could cut regeneration energy by about 30% compared to conventional amine solvents, the findings highlight the need for careful safety screening before industrial scale-up. For anyone working on carbon capture materials, this is a reminder that performance metrics alone are insufficient. Toxicity and occupational exposure limits must be part of the design criteria.
